PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-1.23%
Revenue decline while Medical - Pharmaceuticals median is -0.37%. Seth Klarman would investigate if market share loss is temporary.
-2.48%
Cost reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive advantage potential.
4.03%
Positive growth while Medical - Pharmaceuticals median is negative. Peter Lynch would examine competitive advantages.
5.33%
Margin expansion while Medical - Pharmaceuticals median declines. Peter Lynch would examine competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
G&A reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate efficiency gains.
-100.00%
Marketing expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive implications.
-21.39%
Other expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
1.78%
Operating expenses growth while Medical - Pharmaceuticals reduces costs. Peter Lynch would examine differences.
-1.85%
Total costs reduction while Medical - Pharmaceuticals median is -0.50%. Seth Klarman would investigate advantages.
-11.76%
Interest expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
10.38%
EBITDA growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
11.76%
Margin change of 11.76% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
10.30%
Operating income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
11.68%
Margin change of 11.68% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
229.13%
Other expenses change of 229.13% versus flat Medical - Pharmaceuticals. Walter Schloss would verify control.
16.77%
Pre-tax income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
18.23%
Margin change of 18.23% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
58.01%
Tax expense growth while Medical - Pharmaceuticals reduces burden. Peter Lynch would examine differences.
4.09%
Net income growth exceeding 1.5x Medical - Pharmaceuticals median of 0.07%. Joel Greenblatt would investigate advantages.
5.39%
Margin change of 5.39% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
4.08%
EPS change of 4.08% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
4.08%
Diluted EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 0.81%. Joel Greenblatt would investigate advantages.
-0.00%
Share count reduction while Medical - Pharmaceuticals median is 0.14%. Seth Klarman would investigate strategy.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate strategy.